Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs).

被引：0
|
作者：
Weinstock, Chana
Bandaru, Pradeep
Fernandes, Laura L.
Chang, Elaine
Girvin, Andrew
Tang, Shenghui
Agrawal, Sundeep
Suzman, Daniel L.
Singh, Harpreet
Brave, Michael Holman
Xu, James
Goldberg, Kirsten B.
Ibrahim, Amna
Theoret, Marc Robert
Pazdur, Richard
Beaver, Julia A.
机构：
[1] US FDA, Silver Spring, MD USA
[2] Palantir Technol, Washington, DC USA
[3] Palantir Technol, Menlo Pk, CA USA
[4] Medstar Washington Hosp Ctr, Washington, DC USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] US FDA, Washington, DC USA
[7] NCI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5045
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
    Zhang, Lilong
    Chen, Chen
    Chai, Dongqi
    Li, Chunlei
    Kuang, Tianrui
    Liu, Li
    Dong, Keshuai
    Deng, Wenhong
    Wang, Weixing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
    Nuzzo, Pier Vitale
    Pond, Gregory R.
    Abou Alaiwi, Sarah
    Nassar, Amin H.
    Flippot, Ronan
    Curran, Catherine
    Kilbridge, Kerry L.
    Wei, Xiao X.
    McGregor, Bradley A.
    Choueiri, Toni
    Harshman, Lauren C.
    Sonpavde, Guru
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [33] From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer
    Tambaro, Rosa
    Di Napoli, Marilena
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Attademo, Laura
    Rossetti, Sabrina
    Feroce, Florinda
    Setola, Sergio
    Califano, Daniela
    Russo, Daniela
    Spina, Anna
    Perdona, Sisto
    Izzo, Alessandro
    Pignata, Sandro
    IMMUNOTHERAPY, 2021, 13 (01) : 67 - 77
  • [34] Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs)
    Wu, Linda
    Ozbek, Umut
    van Hyfte, Grace
    Reincke, Marlene
    Gampa, Anuhya
    Abugabal, Yehia I.
    Nishida, Naoshi
    Wietharn, Brooke
    Amara, Suneetha
    Balcar, Lorenz
    Pinter, Matthias
    Vogel, Arndt
    Weinmann, Arndt
    Saeed, Anwaar
    Rimassa, Lorenza
    Naqash, Abdul Rafeh
    Muzaffar, Mahvish
    Huang, Yi-Hsiang
    Pinato, David James
    Ang, Celina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] Impact of concomitant medication use on treatment outcomes in patients with RCC treated with immune checkpoint inhibitors.
    Yildirim, Ahmet
    Wei, Mengting
    Liu, Yuan
    Choi, Yujin
    Suh, Lauren
    Martini, Dylan J.
    Hartman, Caitlin
    Mcclintock, Greta Russler
    Zhuang, Tony Zibo
    Harris, Wayne B.
    Ciuro, Jordan Alana
    Berchuck, Jacob E.
    Brown, Jacqueline T.
    Nazha, Bassel
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [36] Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer
    A. Iglesias-Santamaría
    Clinical and Translational Oncology, 2020, 22 : 1481 - 1490
  • [37] Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer
    Iglesias-Santamaria, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (09): : 1481 - 1490
  • [38] Treatment Response and Clinical Outcomes of Neuroendocrine Neoplasms (NENs) Treated With Immune Checkpoint Inhibitors (ICIs): A Single Institution Experience
    Hauser, Haley
    Le, Tiffany
    Chou, Joanne F.
    Heffernan, Olivia
    DeMore, April
    Gonen, Selin
    Capanu, Marinela
    Reidy-Lagunes, Diane
    Raj, Nitya
    PANCREAS, 2022, 51 (03) : E40 - E40
  • [39] Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
    Hirata, T.
    Uehara, Y.
    Hakozaki, T.
    Terashima, Y.
    Watanabe, K.
    Yomota, M.
    Hosomi, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1659 - S1659
  • [40] Correlation of Survival Outcomes with Clinical and Molecular features in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Chen, R.
    Azzouqa, A. G.
    Zhang, Y.
    Marin-Acevedo, J. A.
    Manochakian, R.
    Lou, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 232 - 232
12345